Assertio Holdings, Inc. (NASDAQ: ASRT) is a pharmaceutical company currently involved in a significant corporate action. The company is in the process of being acquired by Garda Therapeutics, Inc. This acquisition is the primary driver of recent stock activity and provides context for its latest financial reporting.
On May 11, 2026, Assertio Holdings announced revenue of $9.93 million, which surpassed the analyst expectation of $8.97 million. This revenue beat suggests stronger than anticipated sales performance. The company's Price-to-Sales (P/S) ratio is 1.42, which compares the company's stock price to its revenues.
However, the company also reported an earnings per share of -$2.93, missing the consensus estimate of -$2.10. This unprofitability is reflected in its negative Price-to-Earnings (P/E) ratio of -4.17. A negative P/E ratio indicates that the company experienced a net loss over the past year.
The stock's recent movement is mainly tied to the acquisition. As highlighted by Zacks, Assertio Holdings shares surged 17% after Garda Therapeutics raised its buyout offer to $21.80 per share. This revised offer represents a 21.1% increase from the previous bid, bringing the total deal value to over $153 million.
Despite negative earnings, Assertio Holdings shows a solid ability to cover its short-term obligations. The company has a current ratio of 1.82, meaning it has $1.82 in current assets for every $1 of current liabilities. Its Debt-to-Equity ratio is 0.52, indicating manageable debt levels relative to shareholder equity.
